^
Association details:
Biomarker:TP53 mutation
Cancer:Gastric Cancer
Drug:berzosertib (M6620) (ATR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.

Published date:
05/25/2023
Excerpt:
Although the primary endpoint of ORR was not met, the combination of irinotecan and berzosertib in patients with TP53-mutated G/GEJ adenocarcinoma was well-tolerated and demonstrated anti-tumor activity comparable to other agents with published later-line data
Secondary therapy:
irinotecan
DOI:
10.1200/JCO.2023.41.16_suppl.4044
Trial ID: